Search Results
Your search for ,twO matches 12124 pages
Showing 9301 - 9350Increase in Advanced Breast Cancer among Younger Women Is Small but Significant, and Trend Is Likely to Continue
The incidence of advanced breast cancer among women aged 25 to 39 years increased by an average of 2.07% per year from 1976 to 2009 and the trend seems likely to continue, according to an analysis of data for 936,497 women diagnosed with malignant breast cancer. The small but statistically...
Oncology Meetings
May 2013 Annual Paris Melanoma ConferenceMay 2-3 • Paris, FranceFor more information: www.primeoncology.org/parismelanoma2013 5th IMPAKT Breast Cancer ConferenceMay 2-4 • Brussels, BelgiumFor more information: www.esmo.org Florida Society of Clinical Oncology Third Annual AVBCC ConferenceMay 2-5 •...
Rally for Medical Research Draws Thousands in Person and on Social Media
In estimated 10,000 demonstrators filled the streets in front of Washington, DC’s historic Carnegie Library on April 8 to protest budget cuts at the National Institutes of Health. The Rally for Medical Research was held to “emphasize to our policymakers that medical research must become a national...
From One to Many, Here and Around the World
The Conquer Cancer Foundation Grants and Awards Program has grown tremendously in 30 years, from supporting just one researcher in the United States to thousands working around the world. These investigators are performing breakthrough research in all aspects of cancer and making discoveries that...
ASCO's Pre-Annual Meeting Seminar Series to Offer a New, Fourth Focus: Genetics and Genomics
ASCO’s pre–Annual Meeting seminar series continues this year, offering intimate, discussion-based seminars just before the start of the Annual Meeting in late May. The seminars are an excellent educational opportunity for health providers who are attending the Annual Meeting but would like to drill ...
A Promising New Agent's Road to Approval in CLL Raises Questions, Stirs Controversy
Early trial results in single-agent therapy with the oral Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib have produced excellent responses in patients with chronic lymphocytic leukemia (CLL). Moreover, ibrutinib is extremely well tolerated, allowing patients to remain on trial and receive the...
Access to Care: Who Gets Referred to a Medical Oncologist and/or Another Cancer Specialist and Who Receives Treatment for Advanced Cancer?
What factors determine who is referred to a medical oncologist and receives treatment for advanced cancers? Several articles in the Journal of Oncology Practice suggest that factors influencing referral and treatment go beyond the patient’s medical condition and preference and include such details...
Benefit of Continued Antiangiogenic Treatment with Bevacizumab after Progression in Metastatic Colorectal Cancer
As reported recently in Lancet Oncology by Jaafar Bennouna, MD, of Institut de Cancérologie de l’Ouest, Nantes, France, and colleagues, the phase III ML18147 trial showed a survival benefit with continued bevacizumab (Avastin) treatment after first progression in metastatic colorectal cancer.1 The...
Sentinel Node Biopsy in Melanoma: Essential or Optional?
Is sentinel node biopsy in melanoma an essential component of care? Despite a large multinational trial and recently published or updated guidelines, the question is still a thorny one according to experts who debated the issue at the recent meeting of the Society of Surgical Oncology in...
Medical Oncologists Underestimate Resectability of Liver Metastases
Medical oncologists are apt to underestimate the resectability of liver metastases in patients with colorectal cancer and therefore often fail to refer potential surgical candidates for surgical consultation, according to a study presented at the 18th Annual Conference of the National Comprehensive ...
Does Every Melanoma Patient with a Positive Sentinel Node Need More Lymph Nodes Removed?
When sentinel node biopsy was shown to predict whether early melanoma had spread to regional lymph nodes, it revolutionized care. Before that, dissection of all regional lymph nodes was the norm for most patients. After that, the standard of care became a sentinel node biopsy and then—only if the...
Emil 'Tom' Frei III, MD, Trailblazer in the Development of Combination Chemotherapy, Dies at 89
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
High-dose Liposomal Vincristine Produces Durable Responses in Advanced ALL
High-dose monotherapy with vincristine sulfate liposome injection (Marqibo) resulted in meaningful clinical outcomes, including durable responses and bridging to hematopoietic cell transplantation, in adult patients with advanced, relapsed, and refractory Philadelphia chromosome (Ph)-negative acute ...
Exemestane an Adjuvant Option for Postmenopausal Hormone Receptor–positive Breast Cancer
A phase III open-label trial of exemestane vs anastrozole in postmenopausal women with hormone-dependent early breast cancer found that both agents produced similar median rates of event-free survival—91% for exemestane and 91.2% for anastrozole—as well as similar distant disease-free and...
Most Women with Ovarian Cancer Do Not Get Guideline-specified Treatment Linked to Survival Benefits
Most women with ovarian cancer are not receiving adequate treatment, as specified in National Comprehensive Cancer Network (NCCN) Guidelines,1 and as a result are being deprived of the survival benefits correlated with guideline-recommended treatment, according to a study presented at the Society...
Common Deletion in APOBEC3 Genes Associated with Increased Risk of Breast Cancer
Genome-wide association studies have identified numerous genetic susceptibility loci for breast cancer, although these loci explain only a small proportion of heritability. Relatively few studies have assessed associations of breast cancer risk with copy number variation, another important source...
The ASCO Post Up Close: Our Reporters and Contributors
About the Writers Charlotte Bath has been writing about cancer and related fields of medicine since serving as Public Information Director of the American Cancer Society, Long Island Division, from 1975 to 1979. She subsequently worked as a writer for Memorial Sloan-Kettering Cancer Center and...
Drug Approvals in Acute Myeloid Leukemia: Can We Do Better?
Forty years ago, President Richard Nixon announced a “war on cancer.” Some of that war’s first battles were won in the field of acute myeloid leukemia (AML) with two agents, cytarabine and daunorubicin, receiving U.S. Food and Drug Administration (FDA) approval based on their ability to produce...
Focus on Alaska's Denali Oncology Group
Located in Anchorage, Alaska, the Denali Oncology Group faces the dual challenge of serving a diverse and large population of more than 731,000 spread across a vast state of 586,000 square miles, with just 20 medical oncologists and 5 radiation oncologists located mainly in Alaska’s two biggest...
Oncology Meetings
May Northern New England Clinical Oncology Society Spring MeetingMay 17 • Manchester, New HampshireFor more information: www.nnecos.org Iowa Oncology Society Spring Membership ConferenceMay 17-18 • West Des Moines, IowaFor more information: www.ios-iowa.com California Breast Cancer Research...
The Intriguing Potential of S-1 in Pancreatic Cancer
The results of the GEST study by Ueno and colleagues add to the intriguing potential role of the oral fluoropyrimidine S-1 in the treatment of pancreas adenocarcinoma. S-1 is a three-component drug consisting of tegafur (a prodrug of fluorouracil), gimeracil (5-chloro-2,4 dihydropyridine, or CDHP,...
Lynch Syndrome: A Multitude of Predispositions
The current uncertainty regarding the relative frequencies of cancers of various anatomic sites in Lynch syndrome poses a difficulty in commenting on the syndrome’s overall cancer spectrum. It is even more vexing to address the order in which these cancers are prone to occur. What we do know is...
Combinatorial Immunologic Approach Yields Benefit in Preliminary Study of Recurrent Ovarian Cancer
A two-step immunologic approach that includes a personalized dendritic cell vaccine for each patient followed by adoptive T-cell therapy holds promise for the treatment of recurrent ovarian cancer, according to results of two consecutive phase I studies presented at the American Association for...
Guideline Adherence and Geriatric Assessment Studies among NCCN Scientific Posters of Interest
For the first time at the National Comprehensive Cancer Network (NCCN) Annual Conference, scientific posters were included as part of the program. The ASCO Post captured some of the most interesting findings for our readers, including the following news briefs. The findings of these studies support ...
NCCN Patient Guidelines for Adolescents and Young Adults
The National Comprehensive Cancer Network (NCCN) has issued new NCCN Guidelines for Patients, titled “Caring for Adolescents and Young Adults [AYA].” These guidelines fill an unmet need in oncology, as Peter F. Coccia, MD, Chair of the NCCN Guidelines Panel for Young Adult Oncology and a member of...
Automated Telephone Monitoring Reduces Chemotherapy-related Symptoms
The use of an automated computer-based telephone monitoring system to assess symptoms during outpatient chemotherapy—and provide intervention where appropriate by a nurse practitioner—substantially reduced the number of days with symptoms in a study reported at the 18th Annual Conference of the...
Lessons of 2 Decades' Experience with CHESS
Our work on an Internet-based intervention for lung cancer confirmed what many other studies have shown about technologic interventions for health-care consumers—that such interventions can improve quality of life for caregivers and patients.1 We expected this result in part because of the...
Debt and the Oncology Fellow
Despite today’s challenging economy, health care is one field that offers vast career opportunities. Oncology, with the impending workforce shortage, is especially eager for bright young doctors to join its ranks. But the rising costs of medical school can be a deterrent, leading the best and...
Cancer Treatment Pioneers to Share Prize in Medicine and Biomedical Research
Peter C. Nowell, MD, Janet D. Rowley, MD, and Brian J. Druker, MD, have been named as the recipients of the 2013 Albany Medical Center Prize in Medicine and Biomedical Research, to be officially awarded May 17. The $500,000 award, given to those who have altered the course of medical research, is...
Leading Investigators Honored for Outstanding Contributions to the Field of Oncology
Each year through its Special Awards Program, ASCO recognizes researchers, patient advocates, and leaders of the global oncology community who, through their work, have made significant contributions to enhancing cancer care. These recipients of ASCO’s highest, most prestigious awards collectively...
Disparities in Cancer Care: How A Deep South Community Overcame Them
Racial inequities were a daily observation for Edward E. Partridge, MD, growing up in Alabama during the civil rights era. When he became a physician, he saw that these disparities extended into his own field, gynecologic oncology. He decided to do something about it. Dr. Partridge recently...
Majority of Children Readmitted to Hospital Following Stem Cell Transplant
Nearly two-thirds of children receiving stem cell transplants returned to the hospital within 6 months for treatment of unexplained fevers, infections, or other problems, according to a study performed at Dana-Farber/Children’s Hospital Cancer Center in Boston. Children who received donor cells...
Nonmelanoma Skin Cancer May Be Associated with Modest Increased Risk of Secondary Cancer: Further Study Needed
A prospective study by researchers at Brigham and Women’s Hospital observed an association between risk of second primary cancer and history of nonmelanoma skin cancer in white men and women. The researchers found that people with a history of nonmelanoma skin cancer had a modestly increased risk...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
Expert Point of View: Jan A. Burger, MD, PhD
Commenting on this study, Jan A. Burger, MD, PhD, Associate Professor in the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, and first author of one of the ibrutinib studies presented at the 2012 Annual Meeting of the American Society of Hematology, said that...
Promising Phase II Results Continue to Support Ibrutinib in CLL
Results from an ongoing phase II study reported at the recent Annual Meeting of the American Association for Cancer Research (AACR) demonstrate impressive activity with the use of ibrutinib in patients with chronic lymphocytic leukemia (CLL) and 17p deletions, which are associated with a poor...
Autologous Stem Cell Transplant Improves Survival in Transformed Follicular Lymphoma
As reported by the Canadian Blood and Marrow Transplant Group in Journal of Clinical Oncology,1 patients with transformed follicular lymphoma receiving autologous transplantation have improved survival outcomes compared with patients receiving rituximab (Rituxan)-containing chemotherapy alone....
Breakthroughs in Targeted Therapies for Breast Cancer Are Improving Patient Survival Rates
For more than 20 years, José Baselga, MD, PhD, has devoted his medical and scientific career to caring for breast cancer patients and the development of novel molecular targeted agents to treat the disease. From 1996 to 2010, he was Head of the Oncology Department of Vall d’Hebron University...
Reducing Incidental Cardiac Irradiation during Breast Radiotherapy
In the treatment of breast cancer, a wealth of data from prospective clinical trials and meta-analyses has documented the benefits of radiation to prevent local-regional recurrence and improve survival. Accordingly, important quality indicators in breast cancer care include: (1) receipt of...
Novel Approaches to Genetic Testing and Overcoming Treatment Resistance Highlighted at AACR Meeting
Below are brief summaries of highlights from the very full, comprehensive collection of studies presented at the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC. The abstracts describe a potential strategy to overcome resistance and genetic characterization of...
The Tissue Is the Issue: Choosing Therapy for Lung Cancer
The new guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (CAP/IASLC/AMP) are a significant step toward personalized therapy of patients with lung cancer. More than 226,000 new patients per year are...
Expert Point of View: Charles E. Ray, Jr, MD, PhD
Addressing the studies on cryoablation and irreversible electroporation ablation at a Society of Interventional Radiology press briefing, Charles E. Ray, Jr, MD, PhD, Chief of Interventional Radiology at University of Colorado, told The ASCO Post that these novel approaches to metastases are...
Interventional Radiologists Report Novel Approaches for Metastatic Lesions
For the treatment of metastases to the liver and the lung, interventional radiologists reported early success with two novel approaches at the Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, held recently in New Orleans. Cryoablation of Lung Tumors For patients with...
Early Data Promising for Concurrent Sorafenib Plus Embolization in Metastatic Liver Cancer
If sorafenib (Nexavar) and local ablation techniques are both effective in the treatment of metastatic hepatocellular carcinoma, could they deliver an even greater punch when combined? The concurrent use of interventional radiology approaches and sorafenib for metastatic hepatocellular carcinoma is ...
Refractory Liver Metastases Yield to Yttrium-90 Radioembolization
In patients with unresectable hepatic metastases from metastatic melanoma and neuroendocrine tumors, radioembolization led to good outcomes in studies from Emory University School of Medicine reported at the 38th Society of Interventional Radiology Annual Scientific Meeting, held recently in New...
NCCN Clinical Practice Guidelines in Oncology: 2013 Updates
At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), representatives of NCCN Guidelines panels presented two new sets of guidelines along with updates for several tumor types, summarized in this issue of The ASCO Post. New NCCN Guidelines for Survivorship “The...
Profound and Rapid Molecular Remission with CD19-targeted T Cells in Relapsed B-cell ALL
As was recently reported in Science Translational Medicine, Renier J. Brentjens, MD, and colleagues at Memorial Sloan-Kettering Cancer Center, New York, found that profound molecular remission was rapidly induced in patients with relapsed B-cell acute lymphoblastic leukemia (ALL) using autologous T ...
More Recollections on Emil 'Tom' Frei III, MD
I have read with interest the recent tributes to Emil “Tom” Frei III, MD, who passed away in April. I was backstage at the ASCO Annual Meeting in 1981, when Dr. Frei was giving his Karnofsky acceptance address. I had a slide presentation at the combined ASCO/American Association for Cancer Research ...
Patients with Cancer Can Have Cachexia-related Poor Prognostic Factors Regardless of Overall Weight
“Patients with cancer who are cachexic by the conventional criterion (involuntary weight loss) and by two additional criteria (muscle depletion and low muscle attenuation) share a poor prognosis, regardless of overall body weight,” concluded a study in the Journal of Clinical Oncology. Researchers...
Black, Asian, and Younger Women at Increased Risk of PTSD after Diagnosis of Localized Breast Cancer
Nearly one-quarter of women in a large prospective study of racially diverse patients with stage I to III breast cancer reported symptoms consistent with posttraumatic stress disorder (PTSD), with increased risk of PTSD among black, Asian, and younger women. “These potential risk factors can be...
